Abstract

Background. This monocentric study evaluated the effect of Ukrain in the treatment of pancreatic cancer.

Material and methods. Between January 1996 and December 1999 we treated 21 patients with 10 mg Ukrain every second day 210. The control group received supportive treatment only.

Results. Ukrain treatment was well tolerated. Mean values on pain measure and Karnofsky index were significantly better in the Ukrain group than in controls (P<0.05). One-year survival was 76% in the Ukrain group, compared to 9.5% in the control group. Median survival after treatment with Ukrain was 574 days, compared to 197 days in the control group.

Conclusions. Our data demonstrate that Ukrain improves quality of life in patients suffering from advanced pancreatic cancer and significantly prolongs survival time in these patients.